TY - CHAP M1 - Book, Section TI - Antiparasitic Therapy A1 - Bula-Rudas, Fernando J. A2 - Kline, Mark W. PY - 2018 T2 - Rudolph's Pediatrics, 23e AB - Parasitic infections are an important cause of morbidity and mortality worldwide. Parasitic infections occur primarily in the tropical and subtropical areas; nevertheless, due to international travel and immigration, they are becoming important for healthcare practitioners all over the globe. The world of antiparasitic medications can be confusing. Some of the antiparasitic agents are not approved by the US Food and Drug Administration (FDA), and others are approved only for specific indications in children. A few antiparasitic drugs are only available through the Centers for Diseases Control and Prevention (CDC). Several new antiparasitic drugs have become available, and their effectiveness has been determined by their use in countries with endemic infections. Cooperation among governmental and private institutions has made a big impact in helping eradicate or diminish the incidence of parasitic infections in areas with extremely limited resources. Antiparasitic therapy for specific pathogens still could be challenging due to the lack of strong evidence supporting the use for a certain indication. The most recent recommendations for the management of parasitic infections are provided in Tables 318-1, 318-2, 318-3, 318-4, 318-5 including recommended drugs and dosages for specific parasitic infections. Therapy for malaria is discussed in Chapter 347. The CDC also provides a consultation service for healthcare professionals to assist with the management of parasitic infections by phone, Monday through Friday, 7:30 AM to 4:00 PM EST (1-404-718-4745; after-hours emergencies 1-770-488-7100; email: parasites@cdc.gov). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesspediatrics.mhmedical.com/content.aspx?aid=1182903840 ER -